OTCMKTS:OSIR Osiris Therapeutics (OSIR) Stock Price, News & Analysis → The last Republican president? (From The Freeport Society) (Ad) Free OSIR Stock Alerts $18.99 0.00 (0.00%) (As of 04/17/2019) Add Compare Share Share Today's Range$18.99▼$18.9950-Day Range$18.99▼$18.9952-Week Range$7.01▼$19.30VolumeN/AAverage Volume205,753 shsMarket Capitalization$655.69 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Osiris Therapeutics alerts: Email Address Ad The Freeport SocietyThe last Republican president?History shows Donald Trump is poised to go down as the last Republican President for a generation or more. How is this possible, with Biden so unpopular, and Trump running at least neck-in-neck with him in polls?This presentation explains exactly why. About Osiris Therapeutics Stock (OTCMKTS:OSIR)Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.Read More OSIR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OSIR Stock News HeadlinesMay 25, 2024 | finance.yahoo.comGlobal Topical Wound Agents Market Size To Exceed USD 3.7 Billion By 2033 | CAGR Of 6.89%March 19, 2024 | fool.comKanak KantiFebruary 18, 2024 | msn.comMIT's Albumin-based cancer vaccine shows promising results in trialsFebruary 2, 2024 | finance.yahoo.comTissue Engineering Market Set to Soar Past USD 32.45 Billion by 2030January 19, 2024 | finance.yahoo.comAnti-biofilm Wound Dressing Market Size & Share to Surpass US$ 2.3 Billion by 2030 - Exclusive Report by Persistence Market ResearchDecember 29, 2023 | nypost.comNASA launches mission to intercept ‘God of Chaos’ asteroid as it nears Earth’s orbitDecember 11, 2023 | markets.businessinsider.comImmunOs Therapeutics Presents Details of Novel Bispecific Anti-Tumor Molecules at ESMO Immuno-Oncology Congress 2023December 7, 2023 | msn.comIce Age ‘writing system’ to ‘zombie worm’ — 10 biggest science headlines of 2023October 25, 2023 | finance.yahoo.comUNION therapeutics to present at 7th Annual Dermatology Drug Development Summit in BostonOctober 12, 2023 | uk.finance.yahoo.comCoave Therapeutics appoints Leading World Experts to newly formed Scientific Advisory Board dedicated to its Genetic Medicine Delivery PlatformOctober 11, 2023 | finance.yahoo.comWatch NASA reveal its Bennu asteroid samples at 11AM ETOctober 6, 2023 | finance.yahoo.comUNION therapeutics announces presentation of new data on orismilast at the EADV Congress 2023September 28, 2023 | msn.comSuspect shot by police on East Tabor Avenue in FairfieldSeptember 12, 2023 | bizjournals.com10 companies selected as finalists for Coolest Thing Made in Colorado contestSeptember 12, 2023 | msn.comFinalists announced for ‘Coolest Thing Made In Colorado’ competitionSeptember 12, 2023 | msn.comFinalists announced for ‘Coolest Thing Made In Colorado’July 25, 2023 | finance.yahoo.comAmniotic Membrane Global Market Report 2023July 25, 2023 | benzinga.comRegenerative Medicine Market to Grow Rapidly at a CAGR of 21.6% by 2030 | DataM IntelligenceJune 23, 2023 | marketwatch.comUS Cell & Gene Therapy Market Report 2023-2028: Industry Expected to Grow at a CAGR of 41.25% - ResearchAndMarkets.comJune 16, 2023 | benzinga.comRegenerative Medicine Market is expected to grow at a tremendous CAGR of 22.8% during the forecast period 2023-2030May 30, 2023 | finance.yahoo.comTissue Engineering Global Market Report 2023May 23, 2023 | finance.yahoo.comGlobal Cell Therapy Market Report 2023: Growing Approvals for Cell-based Therapies Fuels the SectorMay 22, 2023 | markets.businessinsider.comVesselon Discovery Protects and Expands Drug FranchisesMay 17, 2023 | marketwatch.comBiological Derived Devices Market Reports, Scope, Methodology, Timelines And Challenges Forecast Till 2030May 17, 2023 | marketwatch.comAllogeneic Stem Cells Market Research Report Analysis the Regions, and International Markets Forecast (2023-2030)See More Headlines Receive OSIR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Osiris Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryBiotechnology Current SymbolOTCMKTS:OSIR Previous SymbolNASDAQ:OSIR CUSIP68827R10 CIK1360886 Webwww.osiristx.com Phone443-545-1800FaxN/AEmployeesN/AYear Founded1992Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares34,528,000Free FloatN/AMarket Cap$655.69 million OptionableNot Optionable BetaN/A Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Jason Keefer (Age 46)Interim Pres & CEO Dr. Alla N. Danilkovitch (Age 54)Chief Scientific Officer Mr. Joel David Rogers (Age 56)Interim Chief Financial Officer Mr. Edward YipChief Legal Officer & Corp. Sec.Mr. Laine DyessVP of SalesKey CompetitorsNovavaxNASDAQ:NVAXCelldex TherapeuticsNASDAQ:CLDXMyriad GeneticsNASDAQ:MYGNDynavax TechnologiesNASDAQ:DVAXLigand PharmaceuticalsNASDAQ:LGNDView All Competitors OSIR Stock Analysis - Frequently Asked Questions How have OSIR shares performed in 2024? Osiris Therapeutics' stock was trading at $18.99 at the beginning of the year. Since then, OSIR shares have increased by 0.0% and is now trading at $18.99. View the best growth stocks for 2024 here. What other stocks do shareholders of Osiris Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Osiris Therapeutics investors own include Sierra Wireless (SWIR), Achillion Pharmaceuticals (ACHN), Fate Therapeutics (FATE), Ionis Pharmaceuticals (IONS), Mallinckrodt (MNK), Aerie Pharmaceuticals (AERI), Cytokinetics (CYTK) and Depomed (DEPO). How do I buy shares of Osiris Therapeutics? Shares of OSIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:OSIR) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersGold Prices Surge and This $0.32 Stock Is Reaping The RewardsGold prices are on the rise. This surge in gold prices is great news for gold mining stocks. Especially ...Market JAR | SponsoredBuy this small stock before coming AI Tidal WaveThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of ne...Chaikin Analytics | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredLike Investing in Big Tech in the Early 2000s?More than a decade after the first Bitcoin was mined, people are finally realizing something very important......Manward Press | SponsoredAn utter travestyThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealt...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Osiris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Osiris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.